Lyrical Asset Management LP Takes Position in Icon Plc $ICLR

Lyrical Asset Management LP purchased a new stake in Icon Plc (NASDAQ:ICLR) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 967,961 shares of the medical research company’s stock, valued at approximately $176,382,000. Icon accounts for 2.5% of Lyrical Asset Management LP’s investment portfolio, making the stock its 18th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP boosted its holdings in shares of Icon by 26.6% in the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after buying an additional 975,268 shares during the period. Invesco Ltd. raised its holdings in shares of Icon by 11.1% during the third quarter. Invesco Ltd. now owns 3,427,630 shares of the medical research company’s stock valued at $599,835,000 after acquiring an additional 341,637 shares during the period. Franklin Resources Inc. raised its holdings in shares of Icon by 35.4% during the third quarter. Franklin Resources Inc. now owns 2,753,528 shares of the medical research company’s stock valued at $481,692,000 after acquiring an additional 719,301 shares during the period. Ruane Cunniff & Goldfarb L.P. lifted its position in shares of Icon by 36.2% in the 2nd quarter. Ruane Cunniff & Goldfarb L.P. now owns 1,708,183 shares of the medical research company’s stock valued at $248,455,000 after acquiring an additional 453,833 shares in the last quarter. Finally, Harris Associates L P acquired a new position in Icon in the 2nd quarter worth approximately $238,256,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ICLR shares. Citigroup lifted their price objective on shares of Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, May 29th. Robert W. Baird set a $119.00 target price on Icon in a research report on Friday, February 13th. Bank of America reiterated an “outperform” rating on shares of Icon in a report on Monday, June 1st. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. Finally, BMO Capital Markets lifted their target price on Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research note on Friday, May 29th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $156.44.

Icon Stock Performance

NASDAQ ICLR opened at $149.45 on Monday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The firm’s fifty day simple moving average is $117.51 and its 200-day simple moving average is $140.74. The company has a market capitalization of $11.44 billion, a PE ratio of 24.26, a price-to-earnings-growth ratio of 11.81 and a beta of 1.26.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.21 earnings per share (EPS) for the quarter. Icon had a return on equity of 9.50% and a net margin of 5.98%.The firm had revenue of $2.11 billion during the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. As a group, sell-side analysts anticipate that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.